DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/114d4c/diabetic_foot_ulce) has announced the addition of GlobalData's new report "Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017" to their offering.
Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 report is an essential source of information and analysis on the global diabetic foot ulcer market. The report identifies the key trends shaping and driving the global diabetic foot ulcer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global diabetic foot ulcer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
DFU Therapeutics Market is forecast to Show Two Fold Growth Until 2017
The authors estimated the global DFU therapeutics market to be worth $1,154m in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 10.2% to reach $2,275m by 2017. DFU therapeutics market is contributed by diabetic foot infection (DFI) therapeutics market and DFU wound healing products. The DFI therapeutic market holds the major share of $1,128m of the total DFU therapeutics market. While DFU wound healing therapeutics market is worth only $26m. This high growth forecast is primarily attributed to an increase in the diabetic patient population which will lead to increases in DFU incidence and prevalence, along with emergence of more therapeutic options. The strong product pipeline will complement the existing products by providing effective treatment options. Current Therapeutic Options are Less Successful in Meeting Market Demands
The authors found that the products currently in the market are insufficient to provide protection against the disease with minimum side-effects. Even though most of the anti-infectives are of moderate to high safety and efficacy, the wound healing therapeutics is lagging behind. The unmet need arises from the fact that most of the marketed products are intended to prevent the infection in DFU. So the market is expecting drugs with novel mechanisms of action to accelerate ulcer healing and tissue regeneration.
Strong Pipeline Candidates Will Encourage Competition in DFU Therapeutics Market
The authors found that the product pipeline for DFU is strong, with 29 molecules in various phases of clinical development. There are eight molecules in Phase III, 14 in Phase II and five molecules undergoing Phase I clinical trials. The entry of Pexiganan (pexiganan acetate) for the treatment of mild infections and Fragmin (dalteparin sodium), trafermin and CVBT-141B for wound healing will impact the market. These pipeline products are as safe and efficacious as the current market products with novel formulation or routes of administration. They target the significant unmet need that exists in the market.
Key Topics Covered:
1 Table of contents
2 Diabetic Foot Ulcer (DFU) Therapeutics: Introduction
3 DFU Therapeutics: Market Characterization
4 DFU Therapeutics: Competitive Assessment
5 DFU Therapeutics: Pipeline Assessment
6 DFU Therapeutics: Clinical Trials Mapping
7 DFU Therapeutics: Strategic Assessment
8 DFU Therapeutics: Future Players
9 DFU Therapeutics: Licensing & Partnership Deals
10 DFU Therapeutics: Appendix
Companies Mentioned:
- Pfizer Inc.
- Genaera Corporation
- Cardiovascular Biotherapeutics, Inc
For more information visit http://www.researchandmarkets.com/research/114d4c/diabetic_foot_ulce